Pomerantz Law Firm Files Class Action Against Nektar Therapeutics and Officers
Pomerantz LLP has filed a class action lawsuit against Nektar Therapeutics (NASDAQ: NKTR) and certain officers, alleging violations of federal securities laws. The lawsuit seeks damages for investors who purchased Nektar securities between February 26, 2025, and December 15, 2025. The case is filed in the United States District Court for the Northern District of California.
Tickers: $NKTR
Topics: class action lawsuit Nektar Therapeutics Pomerantz LLP securities fraud